Critical reviews in oncology/hematology最新文献

{"title":"Concomitant chemotherapy in trimodal treatment of patients with muscle invasive bladder cancer: A systematic review of prospective trials","authors":"Camille Baudelin ,&nbsp;Paul Sargos ,&nbsp;Derek Dinart ,&nbsp;Christophe Hennequin ,&nbsp;Diego Teyssonneau ,&nbsp;Lucie Meynard ,&nbsp;Nam-Son Vuong ,&nbsp;Félix Lefort ,&nbsp;Michael Baboudjian ,&nbsp;Guilhem Roubaud","doi":"10.1016/j.critrevonc.2024.104557","DOIUrl":"10.1016/j.critrevonc.2024.104557","url":null,"abstract":"<div><h3>Background and objective</h3><div>For selected patients with muscle-invasive bladder cancer (MIBC), trimodal therapy (TMT) incorporating transurethral resection of the tumor and chemoradiotherapy is an alternative to radical cystectomy. Concurrent chemotherapy (CC) is a pivotal component of TMT, however, the optimal CC protocol remains unknown. This systematic review aims to assess efficacy and safety outcomes of CC protocols used in TMT.</div></div><div><h3>Methods</h3><div>A systematic literature search in the PubMed and Embase databases was performed to identify eligible studies published between 1980 and March 2024. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were followed. Data extraction and risk of bias assessment were performed following predefined criteria.</div></div><div><h3>Key findings and limitations</h3><div>50 studies met the inclusion criteria. Cisplatin-based CC protocols were the most reported. The highest level of evidence was found for 5-fluorouracil and Mitomycin C and for Carbogen-Nicotinamide. However, significant heterogeneity in patient selection, treatment modalities, follow-up and reported outcomes precluded comparison between trials. Outcomes were similar regardless of CC, with 5-year overall survival around 50 %. Bladder preservation rates ranged from 60 % to 90 %. Distant metastasis rates varied from 10 % to 45 %. Locoregional control rates seemed improved with cisplatin combinations despite an increased acute toxicity. Acute and late toxicity were however relatively low across CC protocols. There was no decrease in gastro-intestinal or urinary Quality of Life. Scarce data were available for elderly patients.</div></div><div><h3>Conclusions and clinical implications</h3><div>With similar efficacy and toxicity profiles, and in the absence of comparability among trials, our review does not provide sufficient data to determine the optimal CC for TMT of MIBC. TMT is a well-tolerated and efficient approach with tailored strategy available for patients with localized MIBC.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"205 ","pages":"Article 104557"},"PeriodicalIF":5.5,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142695400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advancing tumor vaccines: Overcoming TME challenges, delivery strategies, and biomaterial-based vaccine for enhanced immunotherapy","authors":"Qingsong Zeng,&nbsp;Shibo Zhang,&nbsp;Ning Leng,&nbsp;Yingying Xing","doi":"10.1016/j.critrevonc.2024.104576","DOIUrl":"10.1016/j.critrevonc.2024.104576","url":null,"abstract":"<div><div>Tumor vaccines, as an immunotherapeutic approach, harness the body's immune cells to provoke antitumor responses, which have shown promising efficacy in clinical settings. However, the immunosuppressive tumor microenvironment (TME) and the ineffective vaccine delivery systems hinder the progression of many vaccines beyond phase II trials. This article begins with a comprehensive review of the complex interactions between tumor vaccines and TME, summarizing the current state of vaccine clinical research. Subsequently, we review recent advancements in targeted vaccine delivery systems and explore biomaterial-based tumor vaccines as a strategy to improve the efficacy of both delivery systems and treatment. Finally, we have presented our perspectives on tumor vaccine development, aiming to advance the field towards the creation of more effective tumor vaccines.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"205 ","pages":"Article 104576"},"PeriodicalIF":5.5,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142704517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prostate-specific membrane antigen as target for vasculature-directed therapeutic strategies in solid tumors","authors":"Jisce R. Puik ,&nbsp;Chung Le ,&nbsp;Geert Kazemier ,&nbsp;Daniela E. Oprea-Lager ,&nbsp;Rutger-Jan Swijnenburg ,&nbsp;Elisa Giovannetti ,&nbsp;Arjan W. Griffioen ,&nbsp;Elisabeth JM Huijbers","doi":"10.1016/j.critrevonc.2024.104556","DOIUrl":"10.1016/j.critrevonc.2024.104556","url":null,"abstract":"<div><div>Prostate-specific membrane antigen (PSMA) is one of the few biomarkers which has been successfully translated to the clinic as theranostic biomarker for patients with prostate cancer. In the context of prostate cancer, PSMA is overexpressed on the cell membrane of tumor cells, making it a viable target for interventions with urea-based small molecule inhibitors or antibodies conjugated to radioactive isotopes. Interestingly, in several non-prostatic cancers, expression of PSMA appears to be associated with the tumor neovasculature. This offers novel therapeutic opportunities for treatments targeting the vasculature in non-prostatic cancers. In this review, we discuss PSMA and its potential as target for vasculature-directed therapeutic approaches, including radioligand therapy, fusion protein vaccination and CAR T-cell therapy.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"205 ","pages":"Article 104556"},"PeriodicalIF":5.5,"publicationDate":"2024-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142650022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The prevalence of solid tumors and hematologic malignancies among patients with Down syndrome: A systematic review and meta-analysis","authors":"Nayara Rozalem Moretti ,&nbsp;Ana Beatriz Nardelli da Silva ,&nbsp;Letícia Vieira Guimarães ,&nbsp;Ian de Paula Bezerra ,&nbsp;João Arthur Cerqueira Taumaturgo ,&nbsp;Natália Gabrielli Silva Alves ,&nbsp;Francinny Alves Kelly ,&nbsp;Francisco Cezar Aquino de Moraes","doi":"10.1016/j.critrevonc.2024.104558","DOIUrl":"10.1016/j.critrevonc.2024.104558","url":null,"abstract":"<div><h3>Background</h3><div>Patients with Down syndrome (DS) have a unique genetic and clinical profile that may increase the risk of cancer.</div></div><div><h3>Methods</h3><div>A literature search on PubMed, Scopus, Web of Science, and the Cochrane databases was conducted, focusing on studies to investigate the prevalence of solid and hematologic tumors in DS.</div></div><div><h3>Results</h3><div>Fifteen studies were included, encompassing 62,121 individuals with Down syndrome (DS). The overall prevalence of cancer in DS was 2.02 % (95 % CI: 1.63–2.50 %). The analysis of hematological tumors revealed a prevalence of 1.18 % (95 % CI: 0.86 % - 1.62 %) for leukemia, 0.86 % (95 % CI: 0.73 % - 1.01 %) for acute lymphoblastic leukemia, and 0.51 % (95 % CI: 0.29 % - 0.90 %) for acute myeloid leukemia. Among solid tumors, testicular cancer had the highest prevalence, at 0.22 % (95 % CI: 0.12 % - 0.43 %).</div></div><div><h3>Conclusions</h3><div>Our results highlight the need for targeted screening strategies, prevention strategies and treatment protocols among those with Down syndrome.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"205 ","pages":"Article 104558"},"PeriodicalIF":5.5,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142644740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Skin barrier dysfunction in cutaneous T-cell lymphoma: From pathogenic mechanism of barrier damage to treatment","authors":"Pengfei Wen ,&nbsp;Xiaoxue Zhuo ,&nbsp;Lin Wang","doi":"10.1016/j.critrevonc.2024.104559","DOIUrl":"10.1016/j.critrevonc.2024.104559","url":null,"abstract":"<div><div>Cutaneous T-cell lymphoma (CTCL) is a group of non-Hodgkin lymphomas characterized by multiple erythematous patches, plaques, or even nodules on the skin. As the disease progresses, patients develop widespread pruritic skin lesions, leading to skin barrier dysfunction, which significantly impacts their quality of life, appearance, and social adaptation. The pathogenesis of CTCL is not fully understood. Recent studies have recognized the important role of skin barrier dysfunction in the development and progression of CTCL, yet a comprehensive review on this topic is lacking. This review summarizes recent findings on skin barrier dysfunction in CTCL, focusing on physical barrier dysfunction, chronic inflammation, and immune dysregulation. We also discuss current and potential therapies aimed at restoring barrier function in CTCL. By emphasizing the integration of barrier-centric approaches into CTCL management, this review provides valuable insights for improving treatment outcomes.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"205 ","pages":"Article 104559"},"PeriodicalIF":5.5,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142644716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A systematic literature review on clonal evolution events preceding relapse in multiple myeloma","authors":"Maja Zimmer Jakobsen ,&nbsp;Rasmus Froberg Brøndum ,&nbsp;Henrik Gregersen ,&nbsp;Hanne Due ,&nbsp;Karen Dybkær","doi":"10.1016/j.critrevonc.2024.104560","DOIUrl":"10.1016/j.critrevonc.2024.104560","url":null,"abstract":"<div><div>Despite considerable treatment advances<strong>,</strong> multiple myeloma (MM) remains an incurable hematological cancer due to treatment resistance. A systematic literature search was conducted to identify determinants for clonal evolution driving relapse and drug resistance in MM. A total of 631 non-duplicate publications were screened of which 28 articles were included for data extraction. Genetic alterations, mutational signatures, evolutionary trajectories, and non-genetic determinants were identified as key topics to characterize clonal evolution in relapsed MM. A variety of factors led to clonal diversification and increased tumor mutation burden, such as MAPK-Ras mutations and incremental changes related to chromosomal bands 1 and 17, while mutational signature analyses revealed that APOBEC activity and melphalan treatment leave a distinct impact on the clonal composition in MM genomes. To capture and dissect tumor heterogeneity, our review suggests combining methods or using technical approaches with high resolution to assess the impact of clonal evolution.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"205 ","pages":"Article 104560"},"PeriodicalIF":5.5,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142644757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Spectrum and genotyping strategies of “dark” genetic matter in germline susceptibility genes of tumor syndromes","authors":"Anikó Bozsik ,&nbsp;Henriett Butz ,&nbsp;Vince Kornél Grolmusz ,&nbsp;Tímea Pócza ,&nbsp;Attila Patócs ,&nbsp;János Papp","doi":"10.1016/j.critrevonc.2024.104549","DOIUrl":"10.1016/j.critrevonc.2024.104549","url":null,"abstract":"<div><h3>Purpose</h3><div>Despite the widespread use of high-throughput genotyping strategies, certain mutation types remain understudied. We provide an overview of these often overlooked mutation types, with representative examples from common hereditary cancer syndromes.</div></div><div><h3>Methods</h3><div>We conducted a comprehensive review of the literature and locus-specific variant databases to summarize the germline pathogenic variants discovered through non-routine genotyping methods. We evaluated appropriate detection and analysis methods tailored for these specific genetic aberrations. Additionally, we performed <em>in silico</em> splice predictions on deep intronic variants registered in the ClinVar database.</div></div><div><h3>Results</h3><div>Our study suggests that, aside from founder mutations, most cases are sporadic. However, we anticipate a relatively high likelihood of splice effects for deep intronic variants. The findings underscore the significant clinical utility of genome sequencing techniques and the importance of applying relevant analysis methods.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"205 ","pages":"Article 104549"},"PeriodicalIF":5.5,"publicationDate":"2024-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142633878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"KRAS mutations in advanced non-small cell lung cancer: From biology to novel therapeutic strategies","authors":"Luigi Liguori ,&nbsp;Fabio Salomone ,&nbsp;Angela Viggiano ,&nbsp;Francesco Sabbatino ,&nbsp;Stefano Pepe ,&nbsp;Luigi Formisano ,&nbsp;Roberto Bianco ,&nbsp;Alberto Servetto","doi":"10.1016/j.critrevonc.2024.104554","DOIUrl":"10.1016/j.critrevonc.2024.104554","url":null,"abstract":"<div><div>Kristen rat sarcoma viral oncogene homolog (<em>KRAS</em>) mutations play a major role in the carcinogenesis of many types of solid tumors including non-small cell lung cancer (NSCLC). Among <em>KRAS</em> mutations, p.G12C single-nucleotide variant (<em>KRAS</em>^{<em>G12C</em>}) is the most frequently reported in NSCLC patients, with a prevalence of about 12–13 %. For many decades, <em>KRAS</em> mutations including <em>KRAS</em>^{<em>G12C</em>} were considered “undruggable” because of the lack of effective and well-tolerated selective therapies. Noteworthy, CodeBreaK100 and KRYSTAL-1 clinical trials have recently demonstrated that sotorasib and adagrasib, two novel selective KRAS^G12C inhibitors, have clinical activity with acceptable adverse-event profile for the treatment of advanced NSCLC patients with <em>KRAS</em>^{<em>G12C</em>} mutation. On the other hand, no selective therapies are approved for the treatment of advanced NSCLC patients with non-G12C <em>KRAS</em> mutations. As a result, these patients receive the same treatments as those without <em>KRAS</em> mutations. In this paper, we describe the role of <em>KRAS</em> mutations in NSCLC focusing on the clinical and molecular characteristics which potentially identify specific subtypes of NSCLC patients based on different <em>KRAS</em> mutations. We also provide an overview of the main clinical trials testing novel selective KRAS^G12C inhibitors as well as novel potential therapeutic strategies for NSCLC patients with non-G12C <em>KRAS</em> mutations.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"205 ","pages":"Article 104554"},"PeriodicalIF":5.5,"publicationDate":"2024-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142633879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expedited pathway insights: Unveiling oncology and non-oncology drug approvals and withdrawals of USFDA and EMA","authors":"Purva Dayanand Chaugule ,&nbsp;Priya Changdev Varpe ,&nbsp;Ankita Arun Tandulje ,&nbsp;Rajeev Singh Raghuvanshi ,&nbsp;Saurabh Srivastava","doi":"10.1016/j.critrevonc.2024.104539","DOIUrl":"10.1016/j.critrevonc.2024.104539","url":null,"abstract":"<div><h3>Background</h3><div>Prior to entering the market, health authorities conduct a rigorous evaluation of compiled information for drugs delaying its entry. To address this void expedited pathways are introduced.</div></div><div><h3>Methods</h3><div>In this study, both oncology and non-oncology drugs approved through various expedited pathways from the US and Europe have been scrutinized using the USFDA’s Novel Drug approvals from 2020 to 2023 and EMA’s Human Medicine Highlights 2020 to 2023. Withdrawals if any along with factors causing withdrawal have also been studied.</div></div><div><h3>Results</h3><div>Among all the pathways accelerated approval has high oncological drug approvals and also high withdrawal for drugs approved based on surrogate endpoints. From the study conducted it was observed that intensive evaluation has to be performed both pre and post-approval for drugs approved based on surrogate endpoints as well as on the conduct of their confirmatory trials.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"205 ","pages":"Article 104539"},"PeriodicalIF":5.5,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142633869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of amino acid PET in radiotherapy target volume delineation for adult-type diffuse gliomas: A review of the literature","authors":"Patrick J. Horsley ,&nbsp;Dale L. Bailey ,&nbsp;Geoffrey Schembri ,&nbsp;Edward Hsiao ,&nbsp;James Drummond ,&nbsp;Michael F. Back","doi":"10.1016/j.critrevonc.2024.104552","DOIUrl":"10.1016/j.critrevonc.2024.104552","url":null,"abstract":"<div><h3>Purpose</h3><div>To summarise existing literature examining amino acid positron emission tomography (AA-PET) for radiotherapy target volume delineation in patients with gliomas.</div></div><div><h3>Methods</h3><div>Systematic search of MEDLINE and EMBASE databases.</div></div><div><h3>Results</h3><div>Twenty studies met inclusion criteria. Studies comparing MRI- and AA-PET- derived target volumes consistently found these to be complementary. Across studies, AA-PET was a strong predictor of the site of subsequent relapse. In studies examining AA-PET-guided radiotherapy at standard doses, including one study using reduced margins, survival outcomes were similar to historical cohorts whose volumes were generated using MRI alone. Four prospective single-arm trials examining AA-PET-guided dose-escalated radiotherapy reported mixed results. The two trials that used both a higher biologically-effective dose and boost-volumes defined using both MRI and AA-PET reported promising outcomes.</div></div><div><h3>Conclusion</h3><div>AA-PET is a promising complementary tool to MRI for radiotherapy target volume delineation, with potential benefits requiring further validation including margin reduction and facilitation of dose-escalation.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"205 ","pages":"Article 104552"},"PeriodicalIF":5.5,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142633880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}